Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12773145 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL6913445 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL13223877 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL3360649 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL12464414 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL12108567 | 0.90 | CYP3A4 (0.65) | CYP3A4CFD | |
| SCHEMBL15668589 | 0.90 | CYP3A4 (0.53) | CYP3A4ROCK2CTSBCFDGRM4 | |
| SCHEMBL13247296 | 0.88 | CYP3A4 (0.43) | CYP3A4ROCK2CTSBGRM4 | |
| SCHEMBL14283027 | 0.88 | CYP3A4 (0.43) | CYP3A4ROCK2CTSBGRM4 | |
| SCHEMBL13385189 | 0.88 | CYP3A4 (0.49) | CYP3A4ROCK2CTSBGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CYP3A4 379/4885ROCK2 3795/4885CTSB 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.